UCB SA (OTCMKTS:UCBJF – Get Free Report) shares crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $192.24 and traded as high as $194.91. UCB shares last traded at $194.90, with a volume of 1,000 shares traded.
UCB Price Performance
The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The firm’s 50-day moving average is $192.20 and its two-hundred day moving average is $185.88.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Recommended Stories
- Five stocks we like better than UCB
- Election Stocks: How Elections Affect the Stock Market
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- What does consumer price index measure?
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
